AstraZeneca (AZN) reported Q2 core earnings Monday of $2.63 per diluted share, up from $2.17 a year earlier.

Analyst polled by FactSet expected $2.49.

Revenue for the quarter ended June 30 was $15.38 billion, compared with $14.46 billion a year earlier.

Analysts expected $15.43 billion.

For 2026, the company continues to expect core EPS to rise by a low double-digit percentage and revenue to grow by a mid-to-high single-digit percentage.

Analysts are looking for $10.24 and $63.18 billion, respectively.